Format

Send to

Choose Destination
PLoS One. 2017 Jul 7;12(7):e0176858. doi: 10.1371/journal.pone.0176858. eCollection 2017.

Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.

Author information

1
Clalit Research Institute, Tel Aviv, Israel.
2
Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
3
Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel.
4
Liver Unit, Beilinson Hospital, Petach Tikva, Israel.
5
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
6
Hepatology, Clalit Health Services, Tel Aviv, Israel.
7
Community Medicine Division, Clalit Health Services, Tel Aviv, Israel.
8
Department of Epidemiology, Faculty of Health Sciences, Ben Gurion University, Be'er Sheva, Israel.

Abstract

BACKGROUND:

Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials.

AIM:

To determine the effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response.

METHODS:

Retrospective observational cohort study of all Clalit Health Services members with hepatitis C virus genotype 1 who were dispensed dasabuvir/ombitasvir/paritaprevir/ritonavir from January 1, 2015 to-November 31, 2015.

RESULTS:

There were 564 participants during the study period. The average age was 61.9 years, 52.0% were male, and 61.5% were born Eastern/Central Europe or Central Asia. The prevalence of diabetes was 31.7% and 70.3% were overweight/obese. Cirrhosis was present in 41.0% of participants, of whom 52.8% had stage 4 fibrosis. Of the cohort, 416 (74.8%) had follow-up viral load testing at 10 or more weeks after the end of treatment. We report a sustained virological response of 98.8% among those tested.

CONCLUSIONS:

Treatment with dasabuvir/ombitasvir/paritaprevir/ritonavir demonstrated a near universal effectiveness in achieving a sustained virological response among HCV patients in a large cohort.

PMID:
28686590
PMCID:
PMC5501432
DOI:
10.1371/journal.pone.0176858
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center